Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(KU 55933; KU55933)
KU-55933 Chemical Structure
|Product name: KU-55933|
|Cat. No.: HY-12016|
KU-55933 is a potent ATM inhibitor with an IC50 and Ki of 13 and 2.2 nM, respectively; highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
IC50 Value: 13 nM
in vitro: KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α.
in vivo: Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β.
|M.Wt||395.49||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||2.5285 mL||12.6425 mL||25.2851 mL|
|5 mM||0.5057 mL||2.5285 mL||5.0570 mL|
|10 mM||0.2529 mL||1.2643 mL||2.5285 mL|
. Choi S, Srivas R, Fu K, Hood BL, Dost B, Gibson GA, Watkins SC, Van Houten B, Bandeira N, Conrads T, Ideker T, Bakkenist CJ.Quantitative proteomics reveals ATM kinase-dependent exchange in DNA damage response complexes.J Proteome Res. 2012 Aug 21.
. Kim YD, Li T, Ahn SW, Kim DK, Lee JM, Hwang SL, Kim YH, Lee CH, Lee IK, Chiang JY, Choi HS.Orphan nuclear receptor SHP negatively regulates growth hormone-mediated induction of hepatic gluconeogenesis through inhibition of STAT5 transactivation.J Biol Chem. 2012 Sep 12.
AZ20 is a potent and selective inhibitor of ATR with an IC50 of 5 nM; 8-fold selectivity over mTOR(IC50=38 nM).
AZD0156 is an oral, potent and selective ATM kinase inhibitor, inhibiting the kinase activity of ATM and ATM-mediated signaling, preventing DNA damage checkpoint activation, and disrupting DNA damage repair, inducing tumor cell apoptosis, and leading to cell death in ATM-overexpressing tumor cells.
AZD6738 is a potent inhibitor of ATR kinase activity with an IC50 of 1 nM against the isolated enzyme and 74 nM against ATR kinase-dependent CHK1 phosphorylation in cells.
CGK 733 is a small molecule inhibitor reportedly targeting the kinase activities of ATM and ATR.
CP-466722 is rapidly reversible potential ATM kinase inhibitor.
ETP-46464 is a cell-permeable quinoline-containing heterotricyclic compound that acts as a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-K(alpha), and ATM (IC50= 0.6, 14, 36, 170, and 545 nM, respectively).
HLM006474 is a potent inhibitor of melanocytes proliferation and subsequent invasion in a three-dimensional tissue culture model system; interferes with E2F activity.
KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM.
VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM.
VE-822 is a selective ATR inhibitor with an Ki value of 0.2 nM, >150 fold selectivity over ATM (Ki=34 nM), DNA-PK (Ki >4 uM) and mTOR (Ki >1 uM).
Other Countries & RegionsSee Worldwide Distributors